Physician profile
Mark A Havera
NPI 1306125166
$1,095.77
in general payments reported to CMS, 2019-2025
8 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $150 · 2021: $136 · 2022: $112 · 2023: $170 · 2024: $215 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549 · Entertainment: $21.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.92 |
| Entertainment | $21.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $435.25 | 2022-2025 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $335.24 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $203.89 | 2021-2025 | Acuvue |
| Coopervision INC. | $43.78 | 2019-2025 | Myday Contact Lens |
| Shire North American Group INC | $23.43 | 2019 | |
| Optos, INC. | $21.68 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $19.92 | 2024 | |
| Abb Con-Cise Optical Group LLC | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Havera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.